GT
FATE icon

Glenmede Trust’s Fate Therapeutics FATE Stock Holding History

Glenmede Trust’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,245
Closed -$207K – 1302
2022
Q3 		$207K Buy
+9,245
New +$267K ﹤0.01% 1079
2020
Q4 		– Sell
-742
Closed -$29K – 1559
2020
Q3 		$29K Buy
742
+712
+2,373% +$24.9K ﹤0.01% 1470
2020
Q2 		$1K Buy
+30
New +$894 ﹤0.01% 2320
2019
Q1 		– Sell
-1,070
Closed -$13K – 3087
2018
Q4 		$13K Buy
+1,070
New +$14.9K ﹤0.01% 2169
2018
Q3 		– Sell
-3,420
Closed -$39K – 1573
2018
Q2 		$39K Buy
+3,420
New +$37.7K ﹤0.01% 1525

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Glenmede Trust's FATE Position: Q4 2022 in Review

Glenmede Trust sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 9,245 shares — an estimated $207K sold.

Glenmede Trust first reported a position in FATE in Q2 2018 and held it in 5 quarters. The position peaked at $207K in Q3 2022. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Glenmede Trust reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Glenmede Trust sold 9,245 Fate Therapeutics shares in Q4 2022, an estimated $207K.
  • Glenmede Trust first reported a position in Fate Therapeutics in Q2 2018 and held it in 5 quarters.
  • Glenmede Trust's Fate Therapeutics position peaked at $207K in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.